Business Wire

DEKA Laser and New York’s Romeo & Juliette: A Global Partnership for Advanced Epilation on Fifth Avenue

4.12.2024 13:00:00 CET | Business Wire | Press release

Share

DEKA Laser, global leader in medical laser technologies, proudly announces its new and prestigious partnership with Romeo & Juliette Hair Removal, the renowned center specialized in permanent hair removal located on world-famous Fifth Avenue in New York City. Thanks to this exclusive collaboration, Romeo & Juliette will become another global reference center for DEKA training on laser hair removal, with particular attention to the Again PRO Series line of equipment, and will host the innovative DEKA Epil Academy, an academy dedicated to the training and sharing of advanced hair removal treatment protocols.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204652458/en/

Located on one of the most elegant and most renowned avenues in the world, Romeo & Juliette Hair Removal is considered true excellence in the aesthetic and medical realm, and is frequented by celebrities, top models and prominent sports personalities. This new international training center will become the reference point for physicians and specialists from all over the world who wish to train on the most innovative and effective laser hair removal protocols, in particular for the treatment of all phototypes.

“The collaboration with Romeo & Juliette represents a significant achievement for DEKA”, says Paolo Salvadeo, DEKA Laser’s CEO. “This partnership allows us to take our quality and innovation standards to one of the most iconic and prestigious locations in the world, making the training experience unique in its type. I am proud to be able to give life to this project, which will contribute to the growth and diffusion of the Again PRO technology and our advanced hair removal protocols.

Also Chris Karavolas, Director of the Romeo & Juliette Center, expresses his enthusiasm for this new phase: “We are thrilled to cooperate with DEKA, a subsidiary of the El.En. Group, an absolute reference company in the world of laser technology. This synergy will allow us to offer cutting-edge treatments to our clients, constantly optimizing the protocols for every skin type. For us working side by side with DEKA and El.En. Group represents a unique growth and development opportunity”.

Chris Karavolas, with over twenty years of experience in the hair removal field, will work closely with the DEKA team to perfect the treatment protocols for every skin type, contributing to positioning Romeo & Juliette and DEKA Laser as global leaders in the sector.

The DEKA Epil Academy will position itself as a center of excellence in the hair removal training, attracting professionals the world over toward the famous Fifth Avenue, a meeting place of innovation, beauty and technology.

https://dekalaser.com/products/again-pro/
https://www.romeojuliettelaserhairremoval.com/

Information on DEKA

DEKA is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.

This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204652458/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye